ASLAN Pharmaceuticals Pte. Ltd. logo

ASLAN Pharmaceuticals Pte. Ltd.

ASLAN Pharmaceuticals is an oncology-focused biotechnology company developing a portfolio of immuno-oncology agents and targeted therapies. ASLAN is a clinical stage pharma company, developing targeted small molecules for the treatment of cancer and autoimmune disorders.

ASLAN licenses preclinical and early clinical compounds from global pharmaceutical companies, focusing on oncology, respiratory and inflammation diseases, and uses the development resources available across Asia to progress the drugs.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://aslanpharma.com
Founded2010
Disease Focus
Development StageClinical
STOCK CODENon Listed
Address
83 Clemenceau Avenue #12-03 UE Square 239920
Singapore
Singapore
Email
Contact Number
+65 6222 4235

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/aslan-pharmaceuticals” connections=”true” suffix=””]

In Jul 2011, ASLAN entered into a license agreement with Array Biopharma under which ASLAN obtained global development rights of ARRY-543/ASLAN001. In Nov 2011, BMS granted rights to develop and commercialize BMS-777607/ASLAN002 in China, Australia, Korea, Taiwan and other selected Asian countries to ASLAN.

In Mar 2012, ASLAN selected PharmaNet/i3 as a strategic partner supporting the clinical development of its oncology portfolio in Asia.

In Dec 2015, ASLAN raised $34 Mn in Series C funding led by Accuron Technologies Limited, a Temasek Holdings subsidiary. Other investors included Tianda Pharmaceuticals Limited, Haitong International, Morningside, Bioveda, Cenova and Sagamore Bioventures. Prior in 2013, ASLAN secured US$22 Mn In Series B Financing.